Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025818 · ClinicalTrials.gov registry record · Phase 3
Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 290
- Enrollment target
NCT00025818 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 290 participants.
The verdict
NCT00025818, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 290 participants
- Enrollment target
Study Summary
A six-month clinical research trial to evaluate the effectiveness of an investigational medication for the treatment of dry eye syndrome in patients that have been diagnosed with moderate to severe dry eye syndrome, an autoimmune disorder AND/OR females 65 years of age or older.
Interventions
- DRUG Ophthalmic Emulsion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2001-05 |
| Est. Completion | 2003-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025818
The ClinicalTrials.gov registry entry for NCT00025818 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ophthalmic Emulsion is the first listed.
NCT00025818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00025818 about?
NCT00025818 is a clinical study titled "Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome". A six-month clinical research trial to evaluate the effectiveness of an investigational medication for the treatment of dry eye syndrome in patients that have been diagnosed with moderate to severe dry eye syndrome, an autoimmune disorder AND/OR females 65 years of age or older.
What is the current status of trial NCT00025818?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 290 participants. The study started on 2001-05. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00025818?
The interventions under investigation include: Ophthalmic Emulsion (DRUG).
Who is sponsoring clinical trial NCT00025818?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.